Form 4: United Therapeutics CEO Executes Planned Stock Sale

Chairperson and CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a 10b5-1 plan.

Summary

• Martine Rothblatt, Chairperson and CEO of United Therapeutics, exercised 9,500 stock options at a strike price of $146.03.
• Following the exercise, the reporting person sold the 9,500 shares in multiple transactions on June 16, 2026.
• The sales were executed at weighted average prices ranging from $545.18 to $554.63 per share.
• The transactions were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.
• The reporting person retains direct ownership of 40,513 shares and significant indirect holdings through various family trusts.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted under a pre-arranged 10b5-1 plan and does not signal a change in company fundamentals.

Positives

• The transactions were executed under a pre-arranged 10b5-1 plan, indicating a systematic approach rather than reactive selling.
• The CEO maintains a substantial remaining equity stake in the company, both directly and through family trusts.

Negatives

• The transaction represents a divestment of shares by the company's top executive.

Risks

• The 10b5-1 plan is scheduled to continue until the earlier of December 31, 2026, or the exercise of 1,734,410 stock options, which may lead to further periodic selling pressure.

Future Outlook

The reporting person's 10b5-1 plan remains active, with the potential for further exercises and sales of up to 1,734,410 options expiring on March 15, 2027, or until December 31, 2026.

Management Comments

• The transactions were conducted pursuant to a pre-arranged 10b5-1 trading plan adopted on November 7, 2025.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is a standard practice for executives to manage personal liquidity and diversify holdings, and is generally viewed as neutral by the market when pre-disclosed.

Comparison to Industry Standards

• The use of 10b5-1 plans is a best-practice standard for corporate executives in the biotechnology sector to avoid allegations of insider trading.
• The scale of the sale relative to the CEO's total beneficial ownership is consistent with typical executive wealth management strategies.

Related Party Transactions

• The reporting person holds shares through various family trusts and shares investment power with immediate family members.

Stakeholder Impact

• Shareholders should note the ongoing, systematic liquidation of options by the CEO, which is expected to continue through the end of 2026.

Next Steps

• Continued execution of the 10b5-1 trading plan through December 31, 2026.

Key Dates

Keywords

United Therapeutics, UTHR, Insider Trading, Martine Rothblatt, 10b5-1, Stock Options